Clinion EDC vs Viedoc:
EDC Software Comparison (2026)
Choosing the right Electronic Data Capture (EDC) system involves much more than comparing eCRFs and edit checks. This guide compares Clinion EDC with Viedoc across key areas including study build, AI capabilities, data review, integrations, usability, and cost, helping you identify the EDC platform that best aligns with your organization’s clinical trial needs.
Clinion EDC or Viedoc – which should you evaluate?
There is no single Electronic Data Capture (EDC) platform that is best for every trial. The right platform depends on your organization, study phase, therapeutic area, operational complexity, integration requirements and the level of automation or AI you expect from your clinical technology stack.
Platforms such as Clinion and Viedoc are among the cloud-based EDC solutions that may be considered for these requirements. The sections below compare these EDC systems using a consistent framework so teams can narrow the list for further evaluation.
| Choose Clinion EDC if… | Choose Viedoc if… |
|---|---|
| Emerging and mid-size CROs, biotech, MedTech, and pharma that want AI-assisted clinical data workflows and a connected platform. | CROs, academic sites, and mid-size sponsors that prioritize user experience, especially in Europe. |
What is EDC software, and what should you compare in 2026?
Electronic Data Capture (EDC) software is used to collect, manage, review and export clinical trial data through electronic case report forms (eCRFs). For regulated studies, teams typically assess or evaluate 21 CFR Part 11, EU Annex 11, GCP, privacy, validation, security and data standards based on study geography and risk.
In 2026, many EDC platforms also connect with broader clinical data management and eClinical workflows leading teams to increasingly compare the complete operating model rather than data capture alone.
Before comparing EDC Software vendors, it helps to define the criteria that matters most for your study and operating model. Most teams evaluate the same core dimensions:
Study build and configuration:
Protocol-to-production speed, whether programming is required, reusable CDASH libraries, and edit-check setup.
Mid-study changes:
Whether visits, forms, fields, and logic can be updated after go-live, and whether that needs downtime or vendor involvement.
Clinical data review:
Query management, discrepancy detection, SDV and remote SDV, centralised and audit-trail review, and medical coding.
Reporting and analytics:
Whether users can build and schedule their own reports without programming, and access data in real time.
AI and automation:
Not whether a vendor ‘has AI,’ but what the AI actually does across setup, coding, extraction, review, and reporting by adding value.
Connected eClinical modules:
Regulatory, security, and standards:
Validation, audit trail, data standards, and the geographies your studies require.
Clinion EDC vs Viedoc: platform-by-platform comparison
A fair profile of each platform: an overview, real strengths, honest considerations, and who it suits.
AI-powered capabilities seamlessly integrated across a unified eClinical platform encompassing EDC, eConsent, RTSM, CTMS, ePRO, eSource and eTMF to streamline clinical trial operations, enhance data quality, and improve operational efficiency.
Strengths
Clinion brings AI-assisted workflows into study build, CDASH mapping, source-to-CRF, medical coding, a DICOM image repository with automatic PHI de-identification, audit-trail review with Ask ATR AI, agentic data review, reporting and query workflows, and remote SDV plus Agentic Assistant for conversational protocol, study operations, and clinical-data querying, with human-in-the-loop review and oversight.
Clinion supports codeless study build configuration through a CDASH-aligned Global Library, real-time mid-study changes without downtime, and study-scoped pricing.
Considerations
Compare how Clinion’s AI-assisted capabilities align with your validation, human-in-the-loop review, and change-control processes. Clinion has also supported studies submitted to the FDA and other regulators, though its overall submission track record is newer than Medidata’s.
Common fit
Emerging and mid-size CROs, biotech, MedTech, and pharma that want AI-assisted clinical data workflows and a connected platform.
Scandinavian-origin cloud EDC known for usability.
Strengths
Drag-and-drop design for eCRFs, workflows, and edit checks, real-time validation, rapid mid-study changes, REST API connectivity, CDISC-compatible formats, and strong study-team self-sufficiency. Consistently high usability ratings and a large third-party review base, plus published tiered pricing.
Considerations
More limited AI-assisted capabilities, a smaller submission library than the enterprise vendors, internet dependence with limited offline support, and maturing support for the most complex studies.
Common fit
CROs, academic sites, and mid-size sponsors that prioritize user experience, especially in Europe.
How Clinion EDC and Viedoc Compare Across Key Features
A side-by-side view of the capabilities clinical data teams evaluate most. This is a shortlisting aid, not a substitute for a formal RFP or a hands-on trial.
Capability | Clinion EDC | Viedoc |
|---|---|---|
AI-powered data management | Full lifecycle | Partial |
In-app AI assistant | Agentic Assistant | – |
No-code study builder | Yes | Yes |
Rapid study build | Global Library | Fast |
Mid-study changes, no downtime | Yes | Yes |
Native eConsent | Yes | Yes |
Native ePRO / eCOA | Yes | Yes |
Native RTSM | Yes | Yes |
Unified eClinical suite | Unified suite | Moderate |
DCT / hybrid ready | Yes | Yes |
Mobile apps | Web-first | Partial |
21 CFR Part 11 / GCP | Yes + ISO | Yes |
Implementation | Self-serve | Fast |
Pricing model | Study-based | Published |
24/7 support | Yes | Included |
Legend: ‘Partial’ or ‘Limited’ means available with restrictions or via integration; ‘Not emphasised’ means not a current public focus; ‘–’ means none noted. Values reflect publicly available product information (vendor sites, G2, Capterra) as of 2026 and are intended for shortlisting only. Capabilities change frequently; verify with each vendor. Clinion’s build, pricing, and module claims are Clinion’s stated figures.
How does AI compare between Clinion EDC and Viedoc?
Traditional EDC automation relies on configured rules, edit checks, and workflows. Newer platforms add AI to different parts of the data lifecycle, but the use cases are not equivalent. The right question is not whether a vendor has AI, but evaluating the task performed, the data used, the level of human oversight required, validation approach and whether the capabilities are available in production environment.
Platform | Primary AI / automation focus |
|---|---|
Clinion | AI study build, CDASH mapping, source-to-CRF, agentic data review, AI reporting and query workflow, remote SDV (rSDV), AI medical coding, DICOM with PHI de-identification, audit-trail review with Ask ATR AI, and the Agentic Assistant, across the clinical data lifecycle with human review |
Viedoc | AI-assisted WHODrug medical coding (Koda) live in production, with human approval; broader AI evolving |
AI capabilities and terminology change quickly. Confirm current, production AI functionality with each vendor.
How to evaluate an EDC vendor’s AI. Ask each vendor to demonstrate a production workflow, then ask: What task does the AI perform? What inputs does it use? Can users approve or reject its output? Is the recommendation traceable in the audit trail? Does it operate on live clinical data? How is it validated, and what happens when the model is uncertain? Answers to these separate genuine, governed AI from a marketing label.
How Do EDC Software Ratings Compare on G2 and Capterra?
Vendor claims are one input; verified user reviews are another. The table below summarises public ratings from G2 and Capterra. Read them alongside review volume, since a high score from a handful of reviews is not equivalent to a slightly lower score from hundreds.
Platform | G2 rating | G2 reviews | Capterra rating | Capterra reviews |
|---|---|---|---|---|
Clinion | 4.6 ★ | 72 | 4.8 ★ | 59 |
Viedoc | 4.5 ★ | 278 | 4.4 ★ | 95 |
Snapshot of publicly listed ratings captured in 2026; some values were not available at capture time. Ratings and counts change continually, so confirm current figures on G2 and Capterra. On Capterra, reviewers also score platforms on ease of use, functionality, value for money, and customer service, which are worth reading directly for your priorities.
How do you choose between Clinion EDC and Viedoc?
Seven steps that separate the right platform from the longest feature list. The prompts in each are what to actually ask or test, not just what to read on a datasheet.
Start with your organization, not the feature list
An emerging biotech running one or two studies has different needs from a global CRO managing dozens of sponsors.
Weigh: speed and cost predictability (biotech), multi-study scalability and sponsor flexibility (CRO), device workflows and long-term follow-up (MedTech), scale and standardization (large pharma).
Evaluate the study-build operating model
The real question is who actually builds and maintains the study.
Compare: vendor-dependent vs certified-specialist-dependent vs self-service no-code vs AI-assisted. This matters more than a binary ‘study builder: yes’.
Test a real protocol amendment
Do not evaluate only the initial demo. Amendments are where platforms diverge.
Ask each vendor to: add a visit, change a field, modify an edit check, publish it while the study is live, and show what happens to existing data.
Compare data review, not just data capture
Modern evaluation extends well beyond entering data.
Check whether reviewers can: find discrepancies, manage queries, review across subjects and forms, run SDV and remote SDV, review audit trails, access external data, generate listings, and move directly from a finding to action.
Understand what ‘AI-powered’ actually means
Require a demonstration of a production workflow, not a slide.
Ask: what task the AI performs, what inputs it uses, whether users can approve or reject output, whether it is traceable, whether it runs on live data, and how it is validated.
Evaluate native integration vs connected products
‘Do you have RTSM?’ is a starting question.
Ask: is it native or a separate product, is there one login, how does subject data synchronise, which system owns the data, and is reconciliation required? Repeat for ePRO/eCOA, eConsent, CTMS, eSource, and eTMF.
Look beyond license price
Total cost of ownership is more than the headline.
Include: licenses, study builds, programming, integrations, validation, training, amendments, reporting, professional services, support, and additional modules.
Where does Clinion EDC fit when comparing it with Viedoc?
Clinion is designed for emerging and mid-size CROs, biotech, MedTech, and pharmaceutical organizations that want configurable EDC combined with AI-assisted clinical data workflows on one connected eClinical modules on one platform.
AI across the clinical data lifecycle
An AI study builder, AI CDASH mapping, source-to-CRF, AI medical coding, a DICOM image repository with automatic PHI de-identification, audit-trail review, and Agentic Assistant for conversational protocol, operations, and clinical-data querying.
Study changes without disruption
Configure and manage post-production changes while maintaining version control and data continuity, without planned downtime.
A connected eClinical environment
EDC linked natively with RTSM, ePRO, eConsent, eSource, CTMS, and eTMF, reducing reconciliation and integration overhead.
Human-controlled AI
AI assists clinical and data-management teams while review, approval, and query actions stay controlled by authorised users.
How We Compared Clinion EDC and Viedoc Across Key Buying Criteria
This comparison draws on publicly available vendor documentation, vendor websites, and third-party software review platforms including G2 and Capterra, as of the review date. Vendor functionality, packaging, and pricing change over time, and Clinion has not independently validated every third-party vendor claim. Organizations should confirm requirements directly with each vendor during their evaluation or RFP process.
Where a capability was unclear or not publicly documented, it is marked accordingly rather than assumed.
Last reviewed: November 2026.
Compare EDC platforms, then see Clinion in your own study
Choosing the right EDC platform goes beyond comparing features. It is about finding a solution that aligns with your study protocol, clinical workflows, operational requirements, and budget.
Discover how Clinion AI can simplify and accelerate your clinical trials through rapid study build, seamless mid-study changes/amendments, efficient data review, and AI-assisted reporting.
Experience Clinion AI with a personalised demonstration tailored to your study requirements and explore how our integrated eClinical platform can improve efficiency, streamline operations, and support data-driven decision-making throughout the clinical trial lifecycle.
Frequently Asked Questions (FAQ)
There is no single EDC that is best for every trial. Emerging and mid-size CROs, biotech, and medical device teams tend to prioritize study-build speed, AI-assisted capabilities, integrated modules, usability, and predictable cost (Clinion, Viedoc).
Match the platform to your organization, study phase, and how much you value AI-assisted capabilities.
EDC is the electronic collection of clinical trial data through electronic case report forms. CDMS is the broader workflow around that data, from capture through cleaning, querying, and database lock. Modern platforms such as Clinion and Medidata offer EDC as one module inside a unified data management suite.
AI within a platform can support tasks ranging from study build, CDASH mapping to coding, discrepancy detection, source-data extraction, reporting, and conversational access to study data. The capabilities vary significantly across platforms.
Clinion integrates AI across multiple stages of the clinical data lifecycle including Agentic Assistant, a multi-agent conversational assistant designed to support study-related workflows and data interactions.
Viedoc: AI-assisted WHODrug medical coding (Koda) live in production, with human approval; broader AI evolving
EDC study-build timelines vary by protocol complexity, library reuse, integrations, validation requirements, amendment strategy, and the vendor operating model. Cloud, no-code platforms with template (libraries) driven approach typically build straightforward studies in roughly two to eight weeks.
Clinion AI accelerates study setup through its standardized, CDASH-aligned Global Library, enabling efficient CRF configuration and streamlined deployment, with an average go-live of around four weeks for typical studies.
Pricing models differ more than headline prices.
Platform | Pricing model |
|---|---|
Clinion EDC | Study-based |
Viedoc | Published |
Viedoc publishes its pricing model (contact sales for pricing).
Clinion uses study-scoped pricing.
Because most vendors quote by study size, compare total cost of ownership, not just licence price.
Multi-study scalability, rapid and repeatable configuration, flexibility for varied sponsor requirements, strong reporting, native integrations across modules, dependable support, and predictable per-study or subscription economics. Clinion is a common CRO choice.
Speed to first patient, low internal resource requirements, no-code configuration, protocol flexibility for amendments, integrated modules, and the ability to scale with the pipeline. Clinion and Viedoc are frequent choices.
Support for device-study designs, long-term and post-market follow-up (including EU MDR PMCF), ePRO/eCOA and eConsent, robust auditability, and regulatory fit. Clinion is commonly considered.
Integrated platforms reduce reconciliation, simplify the audit trail, and cut vendor overhead, which suits lean and mid-size teams. Point solutions can offer deeper specialization but add integration work. When comparing, check whether modules such as RTSM, ePRO/eCOA, and eConsent are native or separate products, whether there is one login, and which system owns the data.
Still have questions?
Explore how Clinion AI can accelerate your trial – reach out to our team.
Unlock the Future of Clinical Trials with Clinion.
Cut your trial costs by 35% and accelerate your time-to-market by 30%